Who Paid My Doc
Max Cadena
Urogynecology and Reconstructive Pelvic Surgery Houston, TX Medical Doctor
NPI 1265938955 CMS profile 4667270
6410 Fannin St Ste 350, Houston, TX 77030
General payments
$3,419
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Max Cadena of Houston, TX is reported in the CMS Open Payments database as having received $3,419 across 30 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 51st percentile of Urogynecology and Reconstructive Pelvic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $20 | 1 | |
| 2024 | General | $226 | 3 | |
| 2023 | General | $2,501 | 19 | |
| 2022 | General | $311 | 3 | |
| 2021 | General | $361 | 4 |
Beside peers
- Max Cadena
- Urogynecology and Reconstructive Pelvic Surgery median
- Middle half of Urogynecology and Reconstructive Pelvic Surgery
- National median
In program year 2025, general payments to Max Cadena were reported at $20. Among 802 Urogynecology and Reconstructive Pelvic Surgery profiles paid that year, the median was $412 and the middle half received between $133 and $1,300.
Show as a table
| Year | Max Cadena | Urogynecology and Reconstructive Pelvic Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $358 | $132–$1,270 | $163 |
| 2020 | $0 | $198 | $86–$642 | $114 |
| 2021 | $361 | $361 | $118–$1,182 | $132 |
| 2022 | $311 | $410 | $128–$1,175 | $149 |
| 2023 | $2,501 | $434 | $152–$1,344 | $160 |
| 2024 | $226 | $494 | $193–$1,331 | $164 |
| 2025 | $20 | $412 | $133–$1,300 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 7 drugsPart D claims
129
Drug cost
$13,491
Branded share of claims
57.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Myrbetriq Mirabegron | Brand | 16 | $6,949 | |
| Gemtesa Vibegron | Brand | 11 | $5,193 | |
| Estradiol | Generic | 15 | $846 | |
| Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst | Brand | 29 | $300 | |
| Ibuprofen | Generic | 16 | $93 | |
| Ondansetron Odt Ondansetron | Brand | 18 | $76 | |
| Oxycodone Hcl | Generic | 24 | $33 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.
Records
30 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Urogynecology and Reconstructive Pelvic Surgery in Texas
Tomas Antonini
Urogynecology and Reconstructive Pelvic Surgery · Austin, TX
Amanda White
Urogynecology and Reconstructive Pelvic Surgery · Austin, TX
Gazala Siddiqui
Urogynecology and Reconstructive Pelvic Surgery · Houston, TX
Fiona Lindo
Urogynecology and Reconstructive Pelvic Surgery · Houston, TX
Peter Lotze
Urogynecology and Reconstructive Pelvic Surgery · Houston, TX
Teresa Irwin
Urogynecology and Reconstructive Pelvic Surgery · San Marcos, TX
Related records
Urogynecology and Reconstructive Pelvic Surgery in Texas
Practitioners in the same specialty and state, ranked by reported value.
All Urogynecology and Reconstructive Pelvic Surgery
Everyone recorded under this specialty, nationwide.
Doctors in Texas
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.